» Articles » PMID: 26473986

Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis

Overview
Specialty Rheumatology
Date 2015 Oct 17
PMID 26473986
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To clarify the relevance of measuring interleukin-6 (IL-6) and C-reactive protein (CRP) levels in order to predict clinical response to tocilizumab (TCZ) in rheumatoid arthritis patients.

Methods: In a pooled, post hoc analysis of 5 pivotal trials of TCZ, we examined the distributions of baseline serum concentrations of IL-6 and CRP, stratified by randomized treatment group, and week 24 Disease Activity Score in 28 joints (DAS28) status (DAS28 <2.6 versus DAS28 ≥2.6). Relationships between early biomarker changes and later changes in DAS28 scores were evaluated using Spearman's correlations and scatterplots. Finally, percentage changes from baseline in IL-6 and CRP levels were evaluated.

Results: Distributions of baseline IL-6 and CRP levels were similar for patients who achieved DAS28 scores <2.6 within 6 months of TCZ initiation and those who did not. Correlations between early changes in these 2 biomarkers and change in DAS28 scores were low (rho < 0.3 for all). Mean percentage increases from baseline in IL-6 concentrations were observed in all treatment groups (highest in the 8 mg/kg dose group); mean percentage decreases in CRP concentrations were greater at week 2 and at all visits for the 8 mg/kg dose group.

Conclusion: Baseline serum concentrations of IL-6 and CRP may not be predictive of clinical outcomes after TCZ treatment. Data demonstrate the efficacy of TCZ in patients across a broad range of baseline serum IL-6 and CRP concentrations. Similarly, changes in these biomarkers after TCZ dosing are expected and may or may not correspond to changes in other clinical signs and symptoms. These results complement previous reports describing the complex interactions among biomarker changes, other therapeutic mechanisms of action, and clinical outcomes.

Citing Articles

Anemia as an indicator of a higher retention rate for tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis from a Korean multi-center registry.

Kim J, Koo B, Lee J, Yoon B J Rheum Dis. 2024; 31(4):212-222.

PMID: 39355549 PMC: 11439637. DOI: 10.4078/jrd.2024.0026.


Multidimensional biomarker approach integrating tumor markers, inflammatory indicators, and disease activity indicators may improve prediction of rheumatoid arthritis-associated interstitial lung disease.

Wan J, Yu Z, Cao X, Zhao X, Zhou W, Zheng Y Clin Rheumatol. 2024; 43(6):1855-1863.

PMID: 38704780 DOI: 10.1007/s10067-024-06984-7.


Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study.

Kumar A, Bhakuni D, Kartik S, Hegde A, Shanmuganandan K, Singh K Eur J Rheumatol. 2022; 9(1):26-30.

PMID: 35110134 PMC: 10089141. DOI: 10.5152/eurjrheum.2021.20202.


Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab.

Moi L, Hamedani M, Ribi C Clin Endocrinol (Oxf). 2021; 97(3):363-370.

PMID: 34908176 PMC: 9545295. DOI: 10.1111/cen.14655.


Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis.

Tsuchiya H, Fujio K Int J Mol Sci. 2021; 22(17).

PMID: 34502442 PMC: 8431405. DOI: 10.3390/ijms22179534.


References
1.
Genovese M, McKay J, Nasonov E, Mysler E, Da Silva N, Alecock E . Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic.... Arthritis Rheum. 2008; 58(10):2968-80. DOI: 10.1002/art.23940. View

2.
Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M . Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005; 5(12):1731-40. DOI: 10.1016/j.intimp.2005.05.010. View

3.
Smolen J, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E . Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371(9617):987-97. DOI: 10.1016/S0140-6736(08)60453-5. View

4.
Smolen J, Landewe R, Breedveld F, Dougados M, Emery P, Gaujoux-Viala C . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69(6):964-75. PMC: 2935329. DOI: 10.1136/ard.2009.126532. View

5.
Singh J, Furst D, Bharat A, Curtis J, Kavanaugh A, Kremer J . 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64(5):625-39. PMC: 4081542. DOI: 10.1002/acr.21641. View